Trial Profile
Phase 2 Study of Clofazimine for the Treatment of Pulmonary Mycobacterium Avium Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Clofazimine (Primary)
- Indications Mycobacterium avium complex infections
- Focus Therapeutic Use
- 16 Jan 2024 Planned End Date changed from 1 Dec 2024 to 1 Apr 2025.
- 16 Jan 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Dec 2024.
- 16 Mar 2023 Planned End Date changed from 1 Oct 2024 to 1 Dec 2024.